Introduction
Due to the particularity of the disease and the metabolic side effects of therapeutic drugs, patients with prostate cancer (PC) are susceptible to metabolic syndrome. Scientific and effective lifestyle interventions may improve the quality of life and survival rate of PC patients, delay or prevent disease progression. An article published in the journal Prostate Cancer Prostatic Dis explores the potential impact of fasting simulated diet (FMD) on PC patients, compiled by Yimaitong as follows.
Research Background
Obesity is a risk factor for disease progression and cancer-specific death in PC patients. Previous animal experiments and Phase II clinical trials have shown that standard treatment combined with FMD is beneficial to reduce weight and delay tumor progression. Based on this, this study evaluated whether periodic FMD is suitable for PC patients and its effect on their metabolic risk factors (NCT04292041).
Study Design
-combination with metabolic syndrome PC patients received periodic FMD (low calories, low sugar , low protein, and high unsaturated fat diet for 4 consecutive days, and returned to normal diet until the next cycle after the end), and a total of 29 patients completed 3 cycles (i.e., 3 months) of FMD. Patients were compared with the weight, abdominal circumference (AC), blood pressure (BP), and laboratory results at 3 months after FMD.
Study Results
After FMD intervention, the main metabolic risk factors of PC patients improved. The average weight of the patient decreased by 3.79 kg (95%CI −5.61 ~ −1.97, p=0.0002); the average weight of the patient was 4.57 cm (95%CI −2.27 ~ −6.87, p=0.0003); the average weight of the patient was 9.52 mmHg (95%CI −16.16 ~ −2.88, p=0.0066) and 4.48 mmHg (95%CI −8.85 ~ −0.43, p=0.0316), respectively. Subgroup analysis stratified by metabolic risk factor (risk degree) showed that FMD had a greater impact on high-risk patients than normal patients, such as patients with baseline systolic blood pressure (−16.04 mmHg, p=0.0001) in patients with baseline systolic blood pressure (−16.04 mmHg, p=0.0001) than those with baseline systolic blood pressure (−0.78 mmHg, p=0.89).
Figure 1 Changes in metabolic risk factors in PC patients (compared with baseline)
study conclusions
This pilot study results show that the application of periodic FMD in PC patients has good safety and high overall patient compliance (83%). Metabolic risk factors improved, and patients' weight, AC and BP overall decreased. Large-scale clinical trials are needed in the future to further evaluate the impact of FMD on metabolic risk factors, quality of life and progression-free survival in PC patients.
References:
Fay-Watt V, O'Connor S, Roshan D, Romeo AC, Longo VD, Sullivan FJ. The impact of a fasting mimicking diet on the metabolic health of a prospective cohort of patients with prostate cancer: a pilot implementation study. Prostate Cancer Prostatic Dis. 2022 Mar 21.
Editor: Wang Mumu
Review: LR
Execution: Wang Mumu
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-